These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25494535)

  • 1. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in silico characterisation of Tacrolimus released under biorelevant conditions.
    Mercuri A; Wu S; Stranzinger S; Mohr S; Salar-Behzadi S; Bresciani M; Fröhlich E
    Int J Pharm; 2016 Dec; 515(1-2):271-280. PubMed ID: 27737809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations.
    Kambayashi A; Kiyota T; Fujiwara M; Dressman JB
    Eur J Pharm Sci; 2019 Jul; 135():83-90. PubMed ID: 31125680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
    Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
    Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
    Kaur N; Narang A; Bansal AK
    Eur J Pharm Biopharm; 2018 Aug; 129():222-246. PubMed ID: 29879527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input.
    Pepin XJH; Sanderson NJ; Blanazs A; Grover S; Ingallinera TG; Mann JC
    Eur J Pharm Biopharm; 2019 Sep; 142():421-434. PubMed ID: 31306753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example.
    Petrakis O; Vertzoni M; Angelou A; Kesisoglou F; Bentz K; Goumas K; Reppas C
    J Pharm Pharmacol; 2015 Jan; 67(1):56-67. PubMed ID: 25252222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A; Hatton GB; Merchant HA; Basit AW
    Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.